Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia

• Status: Completed
• Trial end date: 2013-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Treatments: Iloperidone; Risperidone

Criteria

Inclusion Criteria:

• Men or women ages 18-65 years old.

• DSM-IV diagnosis of schizophrenia.

• PANSS≥70.

• Of the 7 PANSS positive symptom subscale, at least two score ≥ 4 points.

• Written informed consent.

Exclusion Criteria:

• Pregnant or nursing (lactating) women, or women who plan on conceiving during the course of the study.

• Clinically significant disease of the heart,kidneys,liver,hematonosis or endocrine system.